Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Change In Receivables : $-22.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical Change In Receivables?

Ultragenyx Pharmaceutical's change in receivables for the quarter that ended in Dec. 2023 was $1.0 Mil. It means Ultragenyx Pharmaceutical's Accounts Receivable declined by $1.0 Mil from Sep. 2023 to Dec. 2023 .

Ultragenyx Pharmaceutical's change in receivables for the fiscal year that ended in Dec. 2023 was $-22.8 Mil. It means Ultragenyx Pharmaceutical's Accounts Receivable increased by $22.8 Mil from Dec. 2022 to Dec. 2023 .

Ultragenyx Pharmaceutical's Accounts Receivable for the quarter that ended in Dec. 2023 was $73.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ultragenyx Pharmaceutical's Days Sales Outstanding for the three months ended in Dec. 2023 was 52.57.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ultragenyx Pharmaceutical's liquidation value for the three months ended in Dec. 2023 was $-566.4 Mil.

Ultragenyx Pharmaceutical Change In Receivables Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Change In Receivables Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-20.10

9.84

-5.43

-12.07

-22.78

Ultragenyx Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-9.10	-2.51	-15.08	-6.20	1.01

Ultragenyx Pharmaceutical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.8 Mil.

Ultragenyx Pharmaceutical (NAS:RARE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ultragenyx Pharmaceutical's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	73.39	/	127.392	*	91
=	52.57

2. In Ben Graham's calculation of liquidation value, Ultragenyx Pharmaceutical's accounts receivable are only considered to be worth 75% of book value:

Ultragenyx Pharmaceutical's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	577.209	-	1215.599	+	0.75 * 73.39	+	0.5 * 33.969
=	-566.4

Ultragenyx Pharmaceutical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

RARE:Mexico UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Executives

Emil D Kakkis	director, 10 percent owner, officer: President & CEO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg	officer: CBO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn	officer: Chief Financial Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga	officer: Controller and PAO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris	officer: EVP & Chief Commercial Officer	60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion	officer: See Remarks	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer	officer: EVP and General Counsel	60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang	officer: SVP and Chief Tech Ops Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier	officer: CFO & Executive Vice President	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray	director	60 LEVERONI COURT, NOVATO CA 94949
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp	officer: CFO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949